X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Helocyte gains patent rights to use CMV-MVA Triplex, a cytomegalovirus vaccine, in combination with cytomegalovirus-specific, Anti-HIV CAR T Cells for the treatment of adults living with HIV.
Lead Product(s): CMV-MVA Triplex
Therapeutic Area: Infections and Infectious Diseases Product Name: CMV-MVA Triplex
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: City of Hope
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 16, 2023
Details:
The funding will be used for clinical studies of Triplex, a cytomegalovirus (CMV), universal (non-HLA-restricted) recombinant Modified Vaccinia Ankara viral vector vaccine, being developed by Helocyte and City of Hope.
Lead Product(s): CMV-MVA Triplex Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Triplex
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: $3.2 million Upfront Cash: Undisclosed
Deal Type: Funding June 15, 2023
Details:
Triplex is a universal (non-HLA-restricted) recombinant Modified Vaccinia Ankara viral vector vaccine engineered to induce a robust and durable CMV-specific T cell response to three immuno-dominant proteins.
Lead Product(s): CMV-modified Vaccinia Ankara Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Triplex
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
